GLP1R and diabetes mellitus: Further research is also required to assess the comparative effectiveness of glucagon-like peptide-1 receptor agonists with the three alternative second line oral antidiabetic treatments among people with type 2 diabetes mellitus, and to assess how best to personalise the order in which these treatments are prescribed.